Research Summary - 2
Evaluation of arrival viral respiratory vaccine treatment on health outcomes in low- to moderate-risk feedlot steers
| Date/Time: |
9/12/2025
16:45
|
| Author: |
Miles E Theurer |
| Clinic: |
Veterinary Research and Consulting Services, LLC |
| City, State, ZIP: |
Hays, KS 67601 |
M. E. Theurer, DVM, PhD
1
;
J. T. Fox, DVM, MS, PhD
1
;
T. M. McCarty, DVM
1
;
J. R. Newberry, DVM, MS, MBA
2
;
F. Payot, DVM, MS
2
;
1Veterinary Research and Consulting Services, LLC, Hays, KS 67601
2Virbac Corporation, Westlake, TX 76262
Introduction:
Respiratory viral vaccines are used for prevention of bovine respiratory disease (BRD). A total of 6,260 beef steers were used to compare the health outcomes of different arrival vaccine programs comparing were BOVIGENTM Platinum 3 Vaccine (P3), BOVIGENTM Platinum 5 Vaccine (P5), and Bovi-Shield GOLD® 5 (B5).
Materials and methods:
Steers were sorted into three optimal marking groups, and only the medium (n = 3,025) and large-sort (n = 3,235) groups were enrolled into the study. Within each sort-group, steers were randomly assigned to one of the three treatment groups (P3, P5, B5). The individual animal was the experimental unit since all treatment groups were housed within the same lot. A new lot was started once a feedyard pen reached capacity. A subset of steers (n = 1,105) from the medium-sort group had high morbidity and were administered metaphylaxis seven days after arrival process. General and generalized linear mixed models were used for statistical analyses. Data were summarized at 90 days, but closeout data will be completed by conference.
Results:
There were no significant treatment group by metaphylaxis interactions (P > 0.13) within the medium-sort group. There was a significant difference between treatment groups for BRD first treatment (P = 0.01) with P5 having significantly lower BRD first treatment (5.59%) compared to P3 (8.08%; P < 0.01) and tended to have lower BRD first treatment than B5 (6.97%; P = 0.07). No other health outcomes were significantly different.
Significance:
Administering P5 reduced BRD first treatment through 90 days.
